Key achievements in our journey to develop first-in-class therapies for protein misfolding diseases.
December 2024: Completed $130 million oversubscribed Series B financing to advance PROT-001 into pivotal studies for AL amyloidosis.
November 2021: Raised $51 million Series A financing to advance the treatment of protein misfolding diseases and build our pipeline.
PROT-001, our lead drug candidate for AL amyloidosis, is designed to bind and stabilize misfolded light chain proteins.